ReviewEuropean heart journal open2024
Dyslipidaemia management in pregnant patients: a 2024 update.
Review in European heart journal open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Trimester-Specific Serum Lipid Profiles in Gestational Diabetes Mellitus: A Systematic Review, Meta-Analysis, and Meta-Regression.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Investigating the associations between prepregnancy lipoprotein(a) and birth outcomes: The Hispanic Community Health Study/Study of Latinos.Journal of clinical lipidology · 2026Article
- Article
- [Austrian lipid consensus : Interdisciplinary evidence-based recommendations on prevention and treatment of lipid-associated diseases from 15 medical specialist societies].Wiener klinische Wochenschrift · 2026Article
- Familial Hypercholesterolemia in Women: Diagnosis, Treatment, and Cardiovascular Outcomes Across the Lifespan.Current atherosclerosis reports · 2026Review
- Associations of preconception retinal microvasculature with lipid profiles from mid-pregnancy to three months postpartum.NPJ cardiovascular health · 2026Article
- Opportunities and Challenges for Precision Nutrition in Gestational Obesity Management.Current obesity reports · 2026Review
- Gestational Hypertriglyceridemia Management and the Utility of Multidisciplinary Care.JACC. Case reports · 2026Article
- Minimum-Radiation Percutaneous Coronary Intervention for Pregnant Woman With Acute Coronary Syndrome.JACC. Case reports · 2026Article
- Course of Pregnancies and Occurrence of Acute Pancreatitis in Women With Chylomicronemia.The Journal of clinical endocrinology and metabolism · 2026Article
- 2025 Egyptian guidelines for the management of dyslipidemia.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Review
- Safe Continuation of Apheresis during Pregnancy using the Double-Filtration Plasmapheresis Thermo Mode in a Pregnant Female with Familial Hypercholesterolemia: A Case Report.Journal of atherosclerosis and thrombosis · 2026Article
- Prevalence and Correlates of Dyslipidemia in HIV-Positive Patients at Selected Public Hospitals in Addis Ababa, Ethiopia, 2025.AIDS research and treatment · 2026Article
- Navigating hypertriglyceridemia in pregnancy: current evidence and clinical strategies.Frontiers in endocrinology · 2026Review
- From Risk to Resilience: Transforming Perinatal Management for Women with FH.Journal of atherosclerosis and thrombosis · 2025Article
- Brazilian Guideline on Dyslipidemias and Prevention of Atherosclerosis - 2025.Arquivos brasileiros de cardiologia · 2025Article
- Survey on the Current Status of Perinatal Management among Women with Familial Hypercholesterolemia in Japan.Journal of atherosclerosis and thrombosis · 2025Article
- Position Statement on Cardiometabolic Health Across the Woman's Life Course - 2025.Arquivos brasileiros de cardiologia · 2025Article
- Lipid Profile and Management of Dyslipidemias in Pregnancy.Journal of cardiovascular development and disease · 2025Review
- Combined Use of Statin and PCSK9 Inhibitor in a Pregnant Woman with Possible Familial Hypercholesterolemia and Coronary Artery Stenosis.Journal of atherosclerosis and thrombosis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over several decades, the approach to treating dyslipidaemias during pregnancy remains essentially unchanged. The lack of advancement in this field is mostly related to the fact that we lack clinical trials of pregnant patients both with available as well as new therapies. While there are numerous novel therapies developed for non-pregnant patients, there are still many limitations in dyslipidaemia treatment during pregnancy. Besides pharmacotherapy and careful clinical assessment, the initiation of behavioural modifications as well as pre-conception management is very important. Among the various lipid-lowering medications, bile acid sequestrants are the only ones officially approved for treating dyslipidaemia in pregnancy. Ezetimibe and fenofibrate can be considered if their benefits outweigh potential risks. Statins are still considered contraindicated, primarily due to animal studies and human case reports. However, recent systematic reviews and meta-analyses as well as data on familial hypercholesterolaemia (FH) in pregnant patients have indicated that their use may not be harmful and could even be beneficial in certain selected cases. This is especially relevant for pregnant patients at very high cardiovascular risk, such as those who have already experienced an acute cardiovascular event or have homozygous or severe forms of heterozygous FH. In these cases, the decision to continue therapy during pregnancy should weigh the potential risks of discontinuation. Bempedoic acid, olezarsen, evinacumab, evolocumab and alirocumab, and inclisiran are options to consider just before and after pregnancy is completed. In conclusion, decisions regarding lipid-lowering therapy for pregnant patients should be personalized. Despite the challenges in designing and conducting studies in pregnant women, there is a strong need to establish the safety and efficacy of dyslipidaemia treatment during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.